132 related articles for article (PubMed ID: 37786305)
1. Prediction of renal and cardiometabolic outcomes in gout during urate-lowering therapy by sonography.
Calabuig I; Marty-Ané A; Norberciak L; Budzik JF; Legrand J; Martínez-Sanchis A; Pascart T; Andrés M
Int J Rheum Dis; 2023 Dec; 26(12):2450-2459. PubMed ID: 37786305
[TBL] [Abstract][Full Text] [Related]
2. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.
Thiele RG; Schlesinger N
Rheumatol Int; 2010 Feb; 30(4):495-503. PubMed ID: 19543895
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound in gout: a useful tool for following urate-lowering therapy.
Ottaviani S; Gill G; Aubrun A; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Jan; 82(1):42-4. PubMed ID: 25543275
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Rheumatology (Oxford); 2019 Mar; 58(3):410-417. PubMed ID: 30285127
[TBL] [Abstract][Full Text] [Related]
5. Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.
Das S; Goswami RP; Ghosh A; Ghosh P; Lahiri D; Basu K
Mod Rheumatol; 2017 May; 27(3):518-523. PubMed ID: 27492663
[TBL] [Abstract][Full Text] [Related]
6. Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: a 12-month study.
Cipolletta E; Di Battista J; Di Carlo M; Di Matteo A; Salaffi F; Grassi W; Filippucci E
Arthritis Res Ther; 2021 Jul; 23(1):185. PubMed ID: 34243813
[TBL] [Abstract][Full Text] [Related]
7. Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis.
Kampe RT; Nielsen SM; Hotea I; van Durme C; Christensen R; Boonen A
Semin Arthritis Rheum; 2022 Oct; 56():152049. PubMed ID: 35728446
[TBL] [Abstract][Full Text] [Related]
8. The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients.
El-Mallah R; Ibrahim RA; El Attar EA
Curr Rheumatol Rev; 2022; 18(4):338-345. PubMed ID: 36268549
[TBL] [Abstract][Full Text] [Related]
9. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
[TBL] [Abstract][Full Text] [Related]
10. Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.
Helget LN; O'Dell JR; Newcomb JA; Androsenko M; Brophy MT; Davis-Karim A; England BR; Ferguson R; Pillinger MH; Neogi T; Palevsky PM; Wu H; Kramer B; Mikuls TR
Arthritis Rheumatol; 2024 Apr; 76(4):638-646. PubMed ID: 37842953
[TBL] [Abstract][Full Text] [Related]
11. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
[TBL] [Abstract][Full Text] [Related]
12. Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign.
Yuan H; Fan Y; Mou X; Qing Y; Yan X; Tang X; Yue W; Gu P; Yang Q; He Y
Balkan Med J; 2023 Mar; 40(2):104-110. PubMed ID: 36715053
[TBL] [Abstract][Full Text] [Related]
13. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
[TBL] [Abstract][Full Text] [Related]
14. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
15. The value of musculoskeletal ultrasound in predicting gout flares in index joints: A prospective cohort study of people with gout starting urate-lowering therapy.
Han L; Li R; Dalbeth N; Liu M; Yu Q; Jiang C; Ning C; Liu Z; He Y; Li M; Xue X; Jia F; Jia Z; Sun W; Zhang H; Lu J; Wang C; Li C
Semin Arthritis Rheum; 2024 Aug; 67():152418. PubMed ID: 38422901
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.
Peiteado D; Villalba A; Martín-Mola E; Balsa A; De Miguel E
Clin Exp Rheumatol; 2017; 35(5):746-751. PubMed ID: 28281462
[TBL] [Abstract][Full Text] [Related]
17. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study.
Hammer HB; Karoliussen L; Terslev L; Haavardsholm EA; Kvien TK; Uhlig T
Ann Rheum Dis; 2020 Nov; 79(11):1500-1505. PubMed ID: 32669301
[TBL] [Abstract][Full Text] [Related]
19. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study.
Pascart T; Carpentier P; Choi HK; Norberciak L; Ducoulombier V; Luraschi H; Houvenagel E; Legrand J; Verclytte S; Becce F; Budzik JF
Semin Arthritis Rheum; 2021 Aug; 51(4):895-902. PubMed ID: 34198148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
